![]() Outcome measures including the Clinical Global Impressions-Improvement (CGI-I) Scale, Visual Analogue Scale (VAS) for behaviors, and the Aberrant Behavior Checklist (ABC) were administered at baseline, 3 months and 6 months. Investigators and participants were blinded to the randomization. After three months, participants were crossed over to minocycline or placebo as appropriate for the following three months. ![]() Methods Used: Children with FXS ages 3.5–16 years of age were randomized to receive minocycline or placebo. Prior open label human studies suggest benefits. Minocycline decreases matrix metalloproteinase 9 levels and rescues dendritic spine abnormalities in the fragile X knock out mouse. Purpose of Study: The purpose of this study was to determine the efficacy and tolerability of minocycline as a targeted treatment for children with fragile X syndrome (FXS).
0 Comments
Leave a Reply. |